[go: up one dir, main page]

MX2022002766A - Vacunas contra el virus de la gripe y usos de las mismas. - Google Patents

Vacunas contra el virus de la gripe y usos de las mismas.

Info

Publication number
MX2022002766A
MX2022002766A MX2022002766A MX2022002766A MX2022002766A MX 2022002766 A MX2022002766 A MX 2022002766A MX 2022002766 A MX2022002766 A MX 2022002766A MX 2022002766 A MX2022002766 A MX 2022002766A MX 2022002766 A MX2022002766 A MX 2022002766A
Authority
MX
Mexico
Prior art keywords
vaccines against
flu virus
polypeptides
nucleic acids
influenza
Prior art date
Application number
MX2022002766A
Other languages
English (en)
Inventor
Boerries Brandenburg
Johannes Petrus Maria Langedijk
Ferdinand Jacobus Milder
Tina Ritschel
Mandy Antonia Catharina Jongeneelen
Indigo King
Yifan Song
Original Assignee
Janssen Vaccines & Prevention Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Vaccines & Prevention Bv filed Critical Janssen Vaccines & Prevention Bv
Publication of MX2022002766A publication Critical patent/MX2022002766A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/11—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/42—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a HA(hemagglutinin)-tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

En el presente documento se proporcionan polipéptidos de pedúnculo de hemaglutinina de gripe del grupo 2, ácidos nucleicos que codifican dichos polipéptidos, vectores que comprenden dichos ácidos nucleicos y composiciones farmacéuticas que comprenden los mismos, así como métodos para su uso, en particular en la prevención y/o el tratamiento de infecciones por el virus de la gripe.
MX2022002766A 2019-09-05 2020-09-03 Vacunas contra el virus de la gripe y usos de las mismas. MX2022002766A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962896244P 2019-09-05 2019-09-05
PCT/EP2020/074539 WO2021043869A1 (en) 2019-09-05 2020-09-03 Influenza virus vaccines and uses thereof

Publications (1)

Publication Number Publication Date
MX2022002766A true MX2022002766A (es) 2022-04-06

Family

ID=72381076

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022002766A MX2022002766A (es) 2019-09-05 2020-09-03 Vacunas contra el virus de la gripe y usos de las mismas.

Country Status (9)

Country Link
US (1) US12454554B2 (es)
EP (1) EP4025247A1 (es)
JP (1) JP2022547107A (es)
KR (1) KR20220057578A (es)
CN (1) CN114430742A (es)
AU (1) AU2020342463A1 (es)
CA (1) CA3152957A1 (es)
MX (1) MX2022002766A (es)
WO (1) WO2021043869A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117778338A (zh) * 2021-03-24 2024-03-29 华中师范大学 Hppd蛋白、基因、载体、细胞、组合物及其应用、提高作物除草剂抗性的方法
US20250325649A1 (en) * 2021-12-31 2025-10-23 Mynvax Private Limited Polypeptide fragments, immunogenic composition against influenza virus, and implementations thereof
CN120202213A (zh) * 2022-11-14 2025-06-24 扬森疫苗与预防有限公司 乙型流感病毒疫苗及其用途
TW202527960A (zh) * 2023-09-06 2025-07-16 美商賽諾菲巴斯德公司 經修飾ｂ型流感血球凝集素多肽及核酸及其用途

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
US5851806A (en) 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
EP1548118A2 (en) 1994-06-10 2005-06-29 Genvec, Inc. Complementary adenoviral vector systems and cell lines
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US5559099A (en) 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US5965541A (en) 1995-11-28 1999-10-12 Genvec, Inc. Vectors and methods for gene transfer to cells
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
IL122614A0 (en) 1995-06-15 1998-08-16 Introgene Bv Packaging systems for human recombinant adenovirus to be used in gene therapy
US5837511A (en) 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
US6020191A (en) 1997-04-14 2000-02-01 Genzyme Corporation Adenoviral vectors capable of facilitating increased persistence of transgene expression
US5981225A (en) 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
US6113913A (en) 1998-06-26 2000-09-05 Genvec, Inc. Recombinant adenovirus
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
EA017203B1 (ru) 2006-09-07 2012-10-30 Круселл Холланд Б.В. Связывающие молекулы человека, способные нейтрализовать вирус гриппа h5n1, и их применение
CA2761648C (en) 2009-05-11 2019-03-12 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus h3n2 and uses thereof
WO2013007770A1 (en) 2011-07-14 2013-01-17 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza a viruses of phylogenetic group 1 and phylogenetic group 2 and influenza b viruses
MY170927A (en) * 2011-11-28 2019-09-19 Janssen Vaccines & Prevention Bv Influenza virus vaccines and uses thereof
EP3004142B1 (en) 2013-05-30 2020-09-30 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
US10111944B2 (en) 2014-07-10 2018-10-30 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
KR102463632B1 (ko) 2014-07-10 2022-11-03 얀센 백신스 앤드 프리벤션 비.브이. 인플루엔자 바이러스 백신 및 이의 용도
PE20210651A1 (es) * 2018-01-23 2021-03-26 Janssen Vaccines And Prevention B V Vacunas contra virus de la gripe y usos de las mismas

Also Published As

Publication number Publication date
EP4025247A1 (en) 2022-07-13
US12454554B2 (en) 2025-10-28
WO2021043869A1 (en) 2021-03-11
AU2020342463A1 (en) 2022-03-24
US20230250135A1 (en) 2023-08-10
KR20220057578A (ko) 2022-05-09
JP2022547107A (ja) 2022-11-10
CN114430742A (zh) 2022-05-03
CA3152957A1 (en) 2021-03-11

Similar Documents

Publication Publication Date Title
CL2020001901A1 (es) Vacunas contra virus de la gripe y usos de las mismas.
MX2022002766A (es) Vacunas contra el virus de la gripe y usos de las mismas.
MX2017000395A (es) Vacunas contra virus influenza y usos de las mismas.
ECSP21042554A (es) Proteínas f de prefusión del vrs estabilizadas
EP4233898A3 (en) Influenza mrna vaccines
MX2021007679A (es) Anticuerpos humanos para hemaglutinina de influenza.
MX2018014573A (es) Vacuna contra el virus del zika.
MX2019009443A (es) Metodos para tratar la influenza.
MX378904B (es) Vacunas para virus influenza y usos de las mismas.
MX2018012094A (es) Proteinas f de prefusion del virus respiratorio sincicial (vrs) solubles y estabilizadas.
CL2018000320A1 (es) Coadyuvantes basados en aceite (divisional de solicitud 201600650)
MX2019008564A (es) Composiciones inmunogenicas para su uso en vacunas neumococicas.
BR112012020839A2 (pt) vacinas para uso na profilaxe e tratamento de doença de vírus da influenza
MX2017003117A (es) Particula tipo virus de flavivirus.
CO2018010874A2 (es) Vacuna de virus de zika atenuado vivo
MX363464B (es) Vacunas contra influenza h5.
MX380393B (es) Vectores atenuados de influenza para la prevencion y/o tratamiento de enfermedades infecciosas y para el tratamiento de enfermedades oncologicas.
MX2019005979A (es) Peptidos modificados.
BR112019001131A2 (pt) composto virucida, composição farmacêutica, método de desinfecção e/ou esterilização, dispositivo e uso dos compostos virucidas
MX2023007229A (es) Constructo de arn.
MX2018001298A (es) Agente inductor de inmunidad.
BR112022007253A2 (pt) Vacinas contra o vírus influenza e usos das mesmas
AR094846A1 (es) Proteínas h5 del virus de la gripe h5n1 para uso como un medicamento
MX2018003564A (es) 1,4-benzodiazepinas biheteroarilo sustituidas y usos de las mismas para el tratamiento del cancer.
BR112019024796A2 (pt) Peptídeos e usos dos mesmos como agentes antivirais